| HOME >> BIOLOGY >> TECHNOLOGY |
TAI'AN, China, Sept. 24 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 11, 2009, the Company entered into a strategic research and development agreement with the Institute of Blood Transfusion (the "IBT") based in Chengdu, Sichuan Province, to strengthen the Company's research and development capabilities and manufacturing processes. IBT is a division of the Chinese Academy of Medical Sciences and Peking Union Medical College ("CAMS").
The IBT is a leading research institute in China, specializing in a variety of plasma-based research including research on the safety of blood transfusions, blood immunology, transfusion disposable materials, blood biochemistry and molecular biology. China Biologic's collaboration with IBT will include the use of IBT's technology to enhance safe and efficient plasma collection, and increase the range of plasma-derivative products that can be manufactured by the Company. The agreement also entitles China Biologic to utilize IBT's platform technologies, including its recombinant protein therapeutics, monoclonal antibody technology and diagnostics.
China Biologic will collaborate by providing partial funding, plasma, the use of its manufacturing facilities, and access to its research and development resources. IBT will provide specialized training and education to China Biologic's research staff, and will procure additional funding from national and provincial funding bodies. In addition, China Biologic is entitled to the priority purchase rights to commercialize any new technologies or products that result from the collaboration.
"We are committed to being a technology leader in the area of plasma-based
pharmaceuticals and we constantly seek to improve
'/>"/>
| SOURCE China Biologic Products, Inc. Copyright©2009 PR Newswire. All rights reserved |